Advertisement
Australia markets close in 37 minutes
  • ALL ORDS

    7,952.00
    +26.80 (+0.34%)
     
  • ASX 200

    7,698.40
    +22.60 (+0.29%)
     
  • AUD/USD

    0.6534
    -0.0027 (-0.40%)
     
  • OIL

    82.72
    0.00 (0.00%)
     
  • GOLD

    2,164.90
    +0.60 (+0.03%)
     
  • Bitcoin AUD

    100,497.41
    -3,498.10 (-3.36%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6008
    -0.0019 (-0.32%)
     
  • AUD/NZD

    1.0767
    -0.0010 (-0.10%)
     
  • NZX 50

    11,817.91
    +89.90 (+0.77%)
     
  • NASDAQ

    17,985.01
    +176.81 (+0.99%)
     
  • FTSE

    7,722.55
    -4.87 (-0.06%)
     
  • Dow Jones

    38,790.43
    +75.66 (+0.20%)
     
  • DAX

    17,932.68
    -4.02 (-0.02%)
     
  • Hang Seng

    16,550.90
    -186.20 (-1.11%)
     
  • NIKKEI 225

    39,798.91
    +58.51 (+0.15%)
     

Update: Cardiovascular Systems (NASDAQ:CSII) Stock Gained 79% In The Last Year

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. For example, the Cardiovascular Systems, Inc. (NASDAQ:CSII) share price is up 79% in the last year, clearly besting the market return of around 30% (not including dividends). So that should have shareholders smiling. Looking back further, the stock price is 78% higher than it was three years ago.

View our latest analysis for Cardiovascular Systems

Because Cardiovascular Systems made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

ADVERTISEMENT

Over the last twelve months, Cardiovascular Systems's revenue grew by 15%. That's a fairly respectable growth rate. While the share price performed well, gaining 79% over twelve months, you could argue the revenue growth warranted it. If the company can maintain the revenue growth, the share price could go higher still. But before deciding this growth stock is underappreciated, you might want to check out profitability trends (and cash flow)

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:CSII Income Statement, December 20th 2019
NasdaqGS:CSII Income Statement, December 20th 2019

Take a more thorough look at Cardiovascular Systems's financial health with this free report on its balance sheet.

A Different Perspective

It's good to see that Cardiovascular Systems has rewarded shareholders with a total shareholder return of 79% in the last twelve months. That's better than the annualised return of 8.9% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.